IDS and mucopolysaccharidosis type 2: As in our previous post hoc analysis of data from the phase II/III trial and extension study of idursulfase in attenuated MPS II patients over 5 years of age [11], our data do not suggest specific recommendations or modifications be made to the current treatment guidelines associated with the use of idursulfase.